Topic Editors of Frontiers in Pharmacology for the Special Issue “Treating COVID-19 with Currently Available Drugs” Resign in Protest

Four Guest Editors resigned over the egregious treatment of two manuscripts (“REVIEW OF THE EMERGING EVIDENCE DEMONSTRATING THE EFFICACY OF IVERMECTIN IN THE PROPHYLAXIS AND TREATMENT OF COVID-19” and the original research manuscript “HOSPITALIZED COVID-19 PATIENTS TREATED WITH CELECOXIB AND HIGH DOSE FAMOTIDINE ADJUVANT THERAPY SHOW SIGNIFICANT CLINICAL RESPONSES”). Both papers received favorable peer reviews, and yet the papers sat for months unaddressed and then were ultimately rejected. A strong case could be made many COVID-19 patients died unnecessarily due to the delays and ultimate rejection of these papers. The letter concludes: “On behalf of our peers, our institutions, and our scientific and medical colleagues we cannot allow this precedent to remain unchallenged. In our opinion, these unfortunate events constitute gross editorial misconduct by ‘Frontiers’.” The full letter is available in the link below:

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

One thought on “Topic Editors of Frontiers in Pharmacology for the Special Issue “Treating COVID-19 with Currently Available Drugs” Resign in Protest

Leave a Reply

Discover more from Lighthouse Economics

Subscribe now to keep reading and get access to the full archive.

Continue reading